The aggregate market capitalisation of the 20 largest drugmakers grew by 2% overall to reach $4.3tn. Among these, Bristol ...

Despite a robust HIV portfolio and growing oncology sales, Gilead struggles to diversify revenue streams significantly. Learn ...

Watch out, Gilead and Novartis: there's a new CAR-T in town ... U.K. site dubbed “the Nucleus” with Cardinal Health serving as the U.S. commercial distribution partner. The company has wrapped up all ...

On Thursday, Gilead Sciences, Inc. (GILD) stock saw a modest uptick, ending the day at $97.9 which represents a slight increase of $6.21 or 6.77% from the prior close of $91.69. The stock opened at ...

Gilead Sciences, Inc. (NASDAQ:GILD ... The speakers on today's call will be our Chairman and Chief Executive Officer, Daniel O'Day; our Chief Commercial Officer, Johanna Mercier; our Chief Medical ...

Gilead Sciences posted robust revenue and EPS growth, exceeding expectations, and management raised full-year guidance.

Piper Sandler raised the firm’s price target on Gilead (GILD) to $105 from $95 and keeps an Overweight rating on the shares. The firm ...

Despite a mission to become a dominant cancer drug player, Gilead Sciences has as of late been locked in on its ...

Baird raised the firm’s price target on Gilead (GILD) to $95 from $80 and keeps a Neutral rating on the shares. The firm said its was ...

US biotech major Gilead Sciences was trading nearly 2% higher in pre-market on Thursday after announcing its third-quarter ...

Gilead Sciences Canada, Inc. (Gilead Canada) announced today that Paul Petrelli joined the organization as Vice President and ...

BMO Capital Markets analyst Evan Seigerman in a note to investors called Gilead’s third-quarter performance “consistent” and ...